Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma
| Autor: | Peter Foley, Patrick D Mahar, Nick Manuelpillai, Celia M Zubrinich |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
business.industry medicine.drug_class Dermatology Antibodies Monoclonal Humanized medicine.disease Monoclonal antibody Benralizumab Dupilumab Asthma Psoriatic arthritis chemistry.chemical_compound chemistry Rheumatoid arthritis Psoriasis Immunology medicine Humans Female Secukinumab Nasal polyps Anti-Asthmatic Agents business |
| Zdroj: | Australasian Journal of Dermatology. 62:506-508 |
| ISSN: | 1440-0960 0004-8380 |
| Popis: | Biological disease-modifying agents have increasingly become available for the effective treatment of both cutaneous and non-cutaneous inflammatory conditions. We report a case of a woman treated successfully for psoriasis and psoriatic arthritis with the IL-17 inhibitor secukinumab whilst simultaneously being treated for severe asthma and nasal polyps, initially with the IL-5 inhibitor benralizumab, followed by dupilumab, a monoclonal antibody that targets the IL-4 receptor alpha subunit which blocks signalling from both IL-4 and IL-13. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|